Evidence map›Paper›PMID 38426504›Full record

ArticleThe Journal of clinical investigation2024

SGLT2 inhibitors: cardiorenal metabolic drugs for the ages.

Ralph A DeFronzo

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ralph A DeFronzo

Funding

Glycemia Reduction Approaches in Diabetes: A comparative effectiveness studyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI KRAUSE-STEINRAUF, HEIDI, LACHIN, JOHN M · 2012 to 2022
$238.9M
SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · YALE UNIVERSITY · PI RALPH A DEFRONZO · 1986 to 2026
$12.7M
The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGTR01DK097554 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Muhammad Abdul-Ghani · 2012 to 2026
$6.7M
SGLT2 Inhibition and Stimulation of Endogenous Glucose ProductionR01DK107680 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · 2016 to 2026
$5.9M
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizersR01DK129676 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO, Luke Norton · 2022 to 2026
$3.4M
NIDDK NIH HHS R01 DK024092NIDDK NIH HHS R01 DK097554NIDDK NIH HHS R01 DK107680NIDDK NIH HHS R01 DK129676NIDDK NIH HHS U01 DK098246
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID38426504
PMCPMC10904041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.